What this means
Researchers gave older mice a drug called MDL-800 for a long time and checked their spinal discs. The discs looked healthier, but this was done in mice, so it does not show the same effect in people.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- 24-month-old mice
- Kind of research
- Research in animals or cells
The science
- Original title
- SIRT6 Activation Improves Intervertebral Disc Health in the Aging Spine.
- Authors
- Ramteke P, Watson B, Jagannath S et al.
- Journal
- Aging cell
- Published
- Oct 19, 2026
- Study type
- Lab or animal study · indexed as animal research
- PMID
- 42895774 ↗
Abstract
Aging is a critical risk factor for intervertebral disc degeneration, a major contributor to chronic low back pain. Loss-of-function studies showed that SIRT6, a nuclear NAD+-dependent deacetylase, maintains disc health. We therefore investigated whether long-term SIRT6 activation via systemic delivery of the small-molecular agonist MDL-800 improves disc health in 24-month-old mice. Studies revealed healthy disc morphology, enhanced cell viability, and lower degeneration scores following MDL-800 treatment. SIRT6 activation decreased H3K9ac levels, improved extracellular matrix quality, and reduced senescence, as evidenced by lower levels of p21, IL-6, TGF-β, and CCL2. Tissue RNA-Seq, measurements of histone 3 modification, and multi-omics ATAC-seq/RNA-seq revealed altered epigenetic (decreased H3K9ac, H3K36me3, and H3K79me2) and transcriptomic landscapes. MDL-800 increased autophagy without affecting disc cellular bioenergetics. Plasma metabolomics, scRNA-sequencing of lymphoid tissues (bone marrow and spleen), and cytokine profiling showed good systemic tolerance of the treatment. While we noted a small decrease in vertebral structural parameters and mild hyperalgesia in treated cohorts, there were no vertebral fractures, and the broader motor function and behavior remained unaffected, raising no safety concerns. Our studies underscore the feasibility of SIRT6 activation as a pharmacological strategy to maintain the health of the aging spine.
Ramteke P, Watson B, Jagannath S et al. SIRT6 Activation Improves Intervertebral Disc Health in the Aging Spine. Aging cell. 2026. doi:10.1111/acel.70709. PMID: 42895774. https://pubmed.ncbi.nlm.nih.gov/42895774/
Related research
Two drugs together eased stroke brain damage in mice
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes.
Degenerative musculoskeletal disorders, including osteoarthritis (OA), intervertebral disc degeneration (IVDD), and osteoporosis (OP), are increasingly viewed as disorders of mitochondrial quality control (MQC) rather…
Targeting of Protein Persulfidation in Aging and Age-Related Disorders.
Aging is associated with a progressive loss of proteostasis and increased susceptibility to neurodegenerative and metabolic disorders.
Eye supplements that target aging pathways: a review of current evidence
This review looked at vitamins and similar products for eye diseases tied to aging. It says early signs look promising, but long-term benefit is not yet proven.
SIRT1-Redox Crosstalk in Aging: Adaptive Capacity and Cellular State Transitions.
Aging gradually reduces the ability of cells to maintain and restore homeostasis under metabolic and oxidative stress.
Nicotinamide Mononucleotide-Producing Probiotic Strain B12-N Attenuates Aging and Cognitive Decline in a Caenorhabditis elegans Model of Alzheimer's Disease:…
Nicotinamide mononucleotide (NMN) is an active component found in probiotics that may help alleviate Alzheimer's disease and the effects of aging.
See all research on NAD+ boosters →